223 related articles for article (PubMed ID: 26347193)
1. Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples.
Hecht ES; Scholl EH; Walker SH; Taylor AD; Cliby WA; Motsinger-Reif AA; Muddiman DC
J Proteome Res; 2015 Oct; 14(10):4394-401. PubMed ID: 26347193
[TBL] [Abstract][Full Text] [Related]
2. Individuality Normalization when Labeling with Isotopic Glycan Hydrazide Tags (INLIGHT): a novel glycan-relative quantification strategy.
Walker SH; Taylor AD; Muddiman DC
J Am Soc Mass Spectrom; 2013 Sep; 24(9):1376-84. PubMed ID: 23860851
[TBL] [Abstract][Full Text] [Related]
3. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients.
Alley WR; Vasseur JA; Goetz JA; Svoboda M; Mann BF; Matei DE; Menning N; Hussein A; Mechref Y; Novotny MV
J Proteome Res; 2012 Apr; 11(4):2282-300. PubMed ID: 22304416
[TBL] [Abstract][Full Text] [Related]
4. MALDI Mass Spectrometry Imaging of Early- and Late-Stage Serous Ovarian Cancer Tissue Reveals Stage-Specific N-Glycans.
Briggs MT; Condina MR; Ho YY; Everest-Dass AV; Mittal P; Kaur G; Oehler MK; Packer NH; Hoffmann P
Proteomics; 2019 Nov; 19(21-22):e1800482. PubMed ID: 31364262
[TBL] [Abstract][Full Text] [Related]
5. Identification of 34 N-glycan isomers in human serum by capillary electrophoresis coupled with laser-induced fluorescence allows improving glycan biomarker discovery.
Schwedler C; Kaup M; Weiz S; Hoppe M; Braicu EI; Sehouli J; Hoppe B; Tauber R; Berger M; Blanchard V
Anal Bioanal Chem; 2014 Nov; 406(28):7185-93. PubMed ID: 25234305
[TBL] [Abstract][Full Text] [Related]
6. Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.
Ferdosi S; Rehder DS; Maranian P; Castle EP; Ho TH; Pass HI; Cramer DW; Anderson KS; Fu L; Cole DEC; Le T; Wu X; Borges CR
J Proteome Res; 2018 Jan; 17(1):543-558. PubMed ID: 29129073
[TBL] [Abstract][Full Text] [Related]
7. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS.
Wu J; Xie X; Liu Y; He J; Benitez R; Buckanovich RJ; Lubman DM
J Proteome Res; 2012 Sep; 11(9):4541-52. PubMed ID: 22827608
[TBL] [Abstract][Full Text] [Related]
8. Enhanced protocol for quantitative N-linked glycomics analysis using Individuality Normalization when Labeling with Isotopic Glycan Hydrazide Tags (INLIGHT)™.
Kalmar JG; Butler KE; Baker ES; Muddiman DC
Anal Bioanal Chem; 2020 Nov; 412(27):7569-7579. PubMed ID: 32844281
[TBL] [Abstract][Full Text] [Related]
9. ESI-LC-MS Method for Haptoglobin Fucosylation Analysis in Hepatocellular Carcinoma and Liver Cirrhosis.
Zhang Y; Zhu J; Yin H; Marrero J; Zhang XX; Lubman DM
J Proteome Res; 2015 Dec; 14(12):5388-95. PubMed ID: 26503433
[TBL] [Abstract][Full Text] [Related]
10. Plasma N-Glycome Signature of Down Syndrome.
Borelli V; Vanhooren V; Lonardi E; Reiding KR; Capri M; Libert C; Garagnani P; Salvioli S; Franceschi C; Wuhrer M
J Proteome Res; 2015 Oct; 14(10):4232-45. PubMed ID: 26334954
[TBL] [Abstract][Full Text] [Related]
11. Assignment of Core versus Antenna Fucosylation Types in Protein N-Glycosylation via Procainamide Labeling and Tandem Mass Spectrometry.
Nwosu C; Yau HK; Becht S
Anal Chem; 2015 Jun; 87(12):5905-13. PubMed ID: 25978524
[TBL] [Abstract][Full Text] [Related]
12. The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.
Tamir A; Gangadharan A; Balwani S; Tanaka T; Patel U; Hassan A; Benke S; Agas A; D'Agostino J; Shin D; Yoon S; Goy A; Pecora A; Suh KS
J Ovarian Res; 2016 Mar; 9():20. PubMed ID: 27036110
[TBL] [Abstract][Full Text] [Related]
13. Site-specific glycan analysis of human chorionic gonadotropin beta-subunit from malignancies and pregnancy by liquid chromatography--electrospray mass spectrometry.
Valmu L; Alfthan H; Hotakainen K; Birken S; Stenman UH
Glycobiology; 2006 Dec; 16(12):1207-18. PubMed ID: 16880503
[TBL] [Abstract][Full Text] [Related]
14. Comparative profiling of N-glycans isolated from serum samples of ovarian cancer patients and analyzed by microchip electrophoresis.
Mitra I; Alley WR; Goetz JA; Vasseur JA; Novotny MV; Jacobson SC
J Proteome Res; 2013 Oct; 12(10):4490-6. PubMed ID: 23984816
[TBL] [Abstract][Full Text] [Related]
15. Glycans as cancer biomarkers.
Adamczyk B; Tharmalingam T; Rudd PM
Biochim Biophys Acta; 2012 Sep; 1820(9):1347-53. PubMed ID: 22178561
[TBL] [Abstract][Full Text] [Related]
16. Glycomic profiling of targeted serum haptoglobin for gastric cancer using nano LC/MS and LC/MS/MS.
Lee SH; Jeong S; Lee J; Yeo IS; Oh MJ; Kim U; Kim S; Kim SH; Park SY; Kim JH; Park SH; Kim JH; An HJ
Mol Biosyst; 2016 Nov; 12(12):3611-3621. PubMed ID: 27722599
[TBL] [Abstract][Full Text] [Related]
17. Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
Pochechueva T; Chinarev A; Schoetzau A; Fedier A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V
PLoS One; 2016; 11(10):e0164230. PubMed ID: 27764122
[TBL] [Abstract][Full Text] [Related]
18. Two-dimensional HPLC separation with reverse-phase-nano-LC-MS/MS for the characterization of glycan pools after labeling with 2-aminobenzamide.
Wuhrer M; Koeleman CA; Deelder AM
Methods Mol Biol; 2009; 534():79-91. PubMed ID: 19277534
[TBL] [Abstract][Full Text] [Related]
19. Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids.
Kuzmanov U; Musrap N; Kosanam H; Smith CR; Batruch I; Dimitromanolakis A; Diamandis EP
Clin Chem Lab Med; 2013 Jul; 51(7):1467-76. PubMed ID: 23241603
[TBL] [Abstract][Full Text] [Related]
20. Tandem mass spectrometry of isomeric aniline-labeled N-glycans separated on porous graphitic carbon: Revealing the attachment position of terminal sialic acids and structures of neutral glycans.
Michael C; Rizzi AM
Rapid Commun Mass Spectrom; 2015 Jul; 29(13):1268-78. PubMed ID: 26395610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
